At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 12 enrolled
Drug / intervention
Vismodegib +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Clinical Trial Evaluating the Efficacy and Safety of GDC-0449 in Children With Recurrent or Refractory Medulloblastoma
In Brief
A Phase 2 clinical trial evaluating Laboratory Biomarker Analysis, Pharmacological Study, and 1 other intervention for Recurrent Childhood Medulloblastoma. Completed, enrolled 12 participants across 12 sites.
Detailed Summary
This phase II trial studies how well vismodegib works in treating younger patients with recurrent or refractory medulloblastoma. Vismodegib may slow the growth of tumor cells.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRecurrent Childhood Medulloblastoma
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartNov 2010
First PostedNov 2010
Primary CompletionJun 2014
Study CompletionAug 2015
TodayJul 2026
First PostedNov 11, 2010
Enrollment StartNov 1, 2010
Primary CompletionJun 1, 2014
Study CompletionAug 1, 2015
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 15.6 years ago
Interventions
Laboratory Biomarker Analysisother
Correlative studies
Pharmacological Studyother
Correlative studies
Vismodegibdrug
Given PO